NasdaqCM - Delayed Quote USD

Daxor Corporation (DXR)

9.65 -0.06 (-0.62%)
At close: April 26 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DXR

Recent News: DXR

View More
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
GlobeNewswire 12 days ago
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
GlobeNewswire 13 days ago
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
GlobeNewswire 18 days ago
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24

Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
GlobeNewswire 27 days ago
Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript

Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript
Insider Monkey 30 days ago
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
GlobeNewswire last month
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
GlobeNewswire last month
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
GlobeNewswire last month
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
GlobeNewswire last month
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
GlobeNewswire last month
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients
GlobeNewswire last month
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
GlobeNewswire 2 months ago
View More

Related Tickers

HRAL Hear AtLast Holdings, Inc.
0.0010
0.00%
 
PRM.MC Prim, S.A.
10.25
+2.50%
 
BIOT.ST Biotage AB (publ)
165.50
+1.47%
 
GMVDF G Medical Innovations Holdings Ltd
0.0200
+17.65%
 
ALIF-B.ST AddLife AB (publ)
98.65
+2.02%
 
TECN.SW Tecan Group AG
332.60
+1.65%
 
MLSS Milestone Scientific Inc.
0.5600
-1.75%
 
BONEX.ST Bonesupport Holding AB (publ)
232.00
-2.36%
 
NYXH Nyxoah S.A.
10.62
-1.30%
 
ALC.SW Alcon Inc.
72.00
+0.61%